A CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP of the European Pharmacopoeia monograph is often referred to as a CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE Certificate of Suitability (COS). The purpose of a CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE to their clients by showing that a CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP has been issued for it. The manufacturer submits a CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP (COS) as part of the market authorization procedure, and it takes on the role of a CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP holder for the record. Additionally, the data presented in the CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE DMF.
A CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE suppliers with CEP (COS) on PharmaCompass.